Shih-Hua Liu1, K S Clifford Chao2, Yi-Shing Leu3, Jehn-Chuan Lee3, Chung-Ji Liu4, Yu-Chuen Huang5, Yi-Fang Chang6, Hong-Wen Chen1, Jo-Ting Tsai7, Yu-Jen Chen1. 1. Department of Radiation Oncology, Mackay Memorial Hospital, Taipei, Taiwan. 2. Department of Radiation Oncology, Columbia University, New York, New York. 3. Department of Otolaryngology, Mackay Memorial Hospital, Taipei, Taiwan. 4. Department of Oral Surgery, Mackay Memorial Hospital, Taipei, Taiwan. 5. Graduate Institute of Chinese Medical Science, China Medical University, Taichung, Taiwan. 6. Department of Medical Oncology, Mackay Memorial Hospital, Taipei, Taiwan. 7. Department of Radiation Oncology, Taipei Medical University-Shuang Ho Hospital, Taipei, Taiwan.
Abstract
BACKGROUND: Surgery followed by radiotherapy (RT) is indicated for patients with high-risk oral cavity cancer (OCC). Based on multi-institutional reports, we developed a guideline for postoperative RT for patients with OCC. METHODS: A multidisciplinary OCC team was recruited to develop a questionnaire concerning details of risk-factor categorization, target delineation, and dose specification. Thirty-one radiation oncologists from 18 institutions completed the questionnaire, and data were subjected to extensive review to establish the guideline by expert meeting. In this study, we also report the results for patients treated in accordance with the guideline at our institution between 2007 and 2011. RESULTS: Forty-one patients received RT compatible with this guideline with a median 26.8-month follow-up. Thirty-two patients (78%) remained disease-free, 6 (15%) developed locoregional recurrence (4 in-field, 1 marginal, and 1 out-field) and 4 (10%) developed distant metastasis. The overall 2-year survival rate was 86.7%. CONCLUSION: This guideline is promising and should be validated and refined in further clinical practice.
BACKGROUND: Surgery followed by radiotherapy (RT) is indicated for patients with high-risk oral cavity cancer (OCC). Based on multi-institutional reports, we developed a guideline for postoperative RT for patients with OCC. METHODS: A multidisciplinary OCC team was recruited to develop a questionnaire concerning details of risk-factor categorization, target delineation, and dose specification. Thirty-one radiation oncologists from 18 institutions completed the questionnaire, and data were subjected to extensive review to establish the guideline by expert meeting. In this study, we also report the results for patients treated in accordance with the guideline at our institution between 2007 and 2011. RESULTS: Forty-one patients received RT compatible with this guideline with a median 26.8-month follow-up. Thirty-two patients (78%) remained disease-free, 6 (15%) developed locoregional recurrence (4 in-field, 1 marginal, and 1 out-field) and 4 (10%) developed distant metastasis. The overall 2-year survival rate was 86.7%. CONCLUSION: This guideline is promising and should be validated and refined in further clinical practice.